Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Drug

    • Home
    • Drug
    • Page 324
Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody

Fineline Cube Nov 4, 2019

China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...

Drug Medical Device

Shanghai Roche Pharmaceuticals Launches Erlotinib for Advanced Non-Small Cell Lung Cancer in China

Fineline Cube Apr 4, 2007

Shanghai Roche Pharmaceuticals Ltd. made headlines in March with the launch of its lung cancer...

Posts pagination

1 … 323 324

Recent updates

  • Alphamab-CSPC’s HER2 Bispecific Antibody Anbenitamab Wins NMPA Approval for Refractory Gastric Cancer with 75% PFS Benefit
  • Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design
  • CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease
  • Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon
  • Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Alphamab-CSPC’s HER2 Bispecific Antibody Anbenitamab Wins NMPA Approval for Refractory Gastric Cancer with 75% PFS Benefit

Company Drug

Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design

Company Drug

CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease

Company Deals

Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.